Specifications
- Purity
- ≥99% (HPLC)
- Appearance
- White to off white crystalline powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO, methanol, DMF
- Melting Point
- 166 - 169°C
Documentation
- Safety Data Sheet (SDS)
- CDX C0698 MSDS.pdf
Available from stock
Cabozantinib S-malate
- SKU
- C0698
Categories:
- Synonyms
- XL184 malate , BMS907351 malate , N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
- 1140909-48-3
- CAS-Number
- C32H30FN3O10
- Molecular Formula
- 635.59
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- +4°C
- Long Term Storage
- +4°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at +4°C.
- Hazard statements
- H302, H315, H319, H335
- Precautionary statements
- P264, P280, P301+P312, P302+P352, P305+P351+P338, P332+P313, P337+P313
- GHS Symbol
- GHS07
- Transportation
- Not dangerous goods
- Description
- The s-malate salt form of Cabozantinib is very potent orally available inhibitor of multiple receptor tyrosine kinases (RTK), specifically MET and VEGFR2. It also inhibits KIT, FLT3, Tie-2, RET and AXL. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature, angiogenesis and extensive tumor cell apoptosis.
- Smiles
- O[C@@H](CC(O)=O)C(O)=O.COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
- InChi Key
- HFCFMRYTXDINDK-WNQIDUERSA-N
- References
- (1) R. Kurzrock, et al., J. Clin. Oncol. 29, 2660 (2011) , (2) M. Yakes, et al., Mol. Cancer Ther. 10, 2298 (2011) , (3) C. Hage, et al., Cell Death Dis. 4, e627 (2013) , (4) F. Bentzien, et al., Thyroid. 23, 1569 (2013) , (5) Y. Sun, et al., Med. Sci. Monit. 21, 2316 (2015) , (6) J.N. Markowitz & K.M. Fancher, Pharmacotherapy 38, 357 (2018) , (7) C. Gruellich, Recent Results Cancer Res. 211, 67 (2018)
The s-malate salt form of Cabozantinib is very potent orally available inhibitor of multiple receptor tyrosine kinases (RTK), specifically MET and VEGFR2. It also inhibits KIT, FLT3, Tie-2, RET and AXL. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature, angiogenesis and extensive tumor cell apoptosis.
Additional information
| Synonyms | XL184 malate, BMS907351 malate, N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate |
|---|---|
| Purity | ≥99% (HPLC) |
| Appearance | White to off white crystalline powder |
| CAS-Number | 1140909-48-3 |
| Molecular Formula | C32H30FN3O10 |
| Molecular Weight | 635.59 |
| Identity | 1H-NMR |
| Solvents | DMSO, methanol, DMF |
| Melting Point | 166 – 169°C |
| Smiles | O[C@@H](CC(O)=O)C(O)=O.COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2 |
| InChi Key | HFCFMRYTXDINDK-WNQIDUERSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P264, P280, P301+P312, P302+P352, P305+P351+P338, P332+P313, P337+P313 |
| GHS Symbol | GHS07 |
| Transportation | Not dangerous goods |
| References | (1) R. Kurzrock, et al., J. Clin. Oncol. 29, 2660 (2011), (2) M. Yakes, et al., Mol. Cancer Ther. 10, 2298 (2011), (3) C. Hage, et al., Cell Death Dis. 4, e627 (2013), (4) F. Bentzien, et al., Thyroid. 23, 1569 (2013), (5) Y. Sun, et al., Med. Sci. Monit. 21, 2316 (2015), (6) J.N. Markowitz & K.M. Fancher, Pharmacotherapy 38, 357 (2018), (7) C. Gruellich, Recent Results Cancer Res. 211, 67 (2018) |
| Quantity | 100 mg, 500 mg, 1 g, Bulk |
